Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aptarion Biotech AG
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Washington
Beth Israel Deaconess Medical Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University of Washington
University of Cincinnati
National Institutes of Health Clinical Center (CC)
Indiana University
Neonc Technologies, Inc.
Fred Hutchinson Cancer Center
Karolinska Institutet
Thomas Jefferson University
Dana-Farber Cancer Institute
BeOne Medicines
The First Affiliated Hospital with Nanjing Medical University
University of Miami
MeiraGTx UK II Ltd
Ipsen
H. Lee Moffitt Cancer Center and Research Institute
Fondazione Italiana Linfomi - ETS
TICAROS Co., Ltd.
City of Hope Medical Center
Celgene
Brown University
Gilead Sciences
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Washington University School of Medicine
Novartis
H. Lee Moffitt Cancer Center and Research Institute
City of Hope Medical Center
University of Washington
Mayo Clinic
Massachusetts General Hospital
Celgene
University of Washington
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
University of Washington
MeiraGTx UK II Ltd
Regeneron Pharmaceuticals
Novartis
Hope Biosciences Research Foundation
Universität Münster
City of Hope Medical Center
Tel-Aviv Sourasky Medical Center